| Patient | Sarah Walker |
|---|---|
| Date of birth | 1867-12-23 |
| Identifiers | MRN HR-ET019-SYN-TD; SSN (made up) 000-19-7062 |
| Document date | 1917-02-23 |
| Author | Harriet Okonjo-Bell, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week review of the 24-hour ambulatory blood pressure and the repeat kidney tests, with a kidney ultrasound and a nephrology consultation. [S]
Madam Walker returns two weeks after her first visit. She wore the ambulatory monitor for 24 hours on a day at home and has taken home readings morning and evening since, including on a three-day trip; the home average is 152/96. Her morning headaches continue on some days. She has taken no ibuprofen or naproxen. Her office sent the results of last year's executive physical: creatinine 1.18 mg/dL and protein 1+ on a urine dipstick, with no albumin test. She had the kidney ultrasound this morning and then met Dr. Achterberg of nephrology here. She has read about kidney disease and asked directly whether she is heading for dialysis, and what it would take to avoid it without giving up her travel. [S]
| Element | Detail |
|---|---|
| Ambulatory monitoring | 24-hour mean 149/94; daytime 154/98; night 140/88 |
| Home blood pressure | Average 152/96 over seven days, travel days included |
| Earlier results | Creatinine 1.18 mg/dL and dipstick protein 1+ about a year ago |
| Kidney ultrasound | This morning |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or weight loss |
| Neurological | Positive | Morning headaches on some days; no weakness or vision loss |
| Cardiovascular | Negative | No chest pain, palpitations or ankle swelling |
| Genitourinary | Negative | No blood in the urine; gets up once at night to pass urine |
| Musculoskeletal | Negative | No joint pain or rash |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Losartan 50 mg oral tablet, one tablet each morning | One tablet each morning, at the same home time when traveling | Oral route | 1917-02-23 to 1917-03-09 | completed | S |
| Empagliflozin 10 mg oral tablet, one tablet each morning; stop on days of vomiting, diarrhea or not eating, and before surgery | One tablet each morning, with sick-day rules | Oral route | 1917-02-23 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1917-02-23 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1917-02-23 | Body height | 163 | cm | S |
| 1917-02-23 | Body weight | 78.6 | kg | S |
| 1917-02-23 | Body mass index (BMI) [Ratio] | 29.6 | kg/m2 | S |
| 1917-02-23 | Systolic blood pressure | 160 | mm[Hg] | S |
| 1917-02-23 | Diastolic blood pressure | 100 | mm[Hg] | S |
| 1917-02-23 | Heart rate | 80 | /min | S |
| 1917-02-23 | Respiratory rate | 16 | /min | S |
| 1917-02-23 | Body temperature | 36.6 | Cel | S |
| 1917-02-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1917-02-23 | Albumin/Creatinine [Mass Ratio] in Urine | 294 | mg/g | Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2); above 300 severely increased (A3) | High | S |
| 1917-02-23 | Creatinine [Mass/volume] in Serum or Plasma | 1.21 | mg/dL | 0.59-1.04 mg/dL | High | S |
| 1917-02-23 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1912)/1.73 sq M | 55 | mL/min/{1.73_m2} | 60 or higher (G1 to G2) unless other kidney damage; 45 to 59 is G3a | Low | S |
| 1917-02-23 | Calcium [Mass/volume] in Serum or Plasma | 9.4 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 1917-02-23 | Phosphate [Mass/volume] in Serum or Plasma | 3.6 | mg/dL | 2.5-4.5 mg/dL | Normal | S |
| 1917-02-23 | Parathyrin.intact [Mass/volume] in Serum or Plasma | 58 | pg/mL | 15-65 pg/mL | Normal | S |
| 1917-02-23 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 31 | ng/mL | 30-100 ng/mL | Normal | S |
Vital signs recorded on 1917-02-23; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 160/100 (average of two readings), pulse 80; weight 78.6 kg |
| Cardiovascular | Regular rhythm; sustained apex beat; no murmur or bruit; no ankle swelling |
| Respiratory | Clear |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Elevated blood pressure at intake (166/102 mmHg, average of two readings), first found at a workplace screening; ambulatory monitoring to confirm | resolved | confirmed | R03.0 | S — Synthetic presenting finding, superseded by the confirmed diagnosis at two weeks. |
| Albumin in the urine (urine albumin-to-creatinine ratio 286 mg/g) with eGFR 54 by the race-free CKD-EPI 1912 equation; she recalls protein in the urine at an executive physical a year ago, and those records are requested; to be repeated and investigated | resolved | confirmed | R80.9 | S — Synthetic presenting finding, superseded by the kidney diagnosis at two weeks. |
| Hypertension, stage 2, confirmed by 24-hour ambulatory monitoring (24-hour mean 149/94, daytime 154/98, night 140/88 without the normal nighttime fall), with left ventricular hypertrophy on ECG and mild hypertensive retinopathy; synthetic modern episode linked to her documented high blood pressure | active | confirmed | I12.9 | S — Synthetic modern diagnosis anchored to the documented hypertension and nephritis. |
| Chronic kidney disease G3a A2 (eGFR 54 to 55 mL/min/1.73 m2 by the race-free CKD-EPI 1912 equation; albumin-to-creatinine ratio 286 to 294 mg/g; present for more than three months), most likely hypertensive kidney disease; bland urine sediment and normal-sized kidneys on ultrasound; 5-year kidney failure risk 1.6% | active | confirmed | N18.31 | S — Synthetic kidney findings anchored to the documented nephritis and death from kidney disease. |
| Hyperlipidemia: LDL 174 mg/dL; 10-year ASCVD risk 7.9% by the Pooled Cohort Equations (intermediate) | active | confirmed | E78.5 | S — Synthetic laboratory finding. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Office blood pressure (seated, five minutes' rest, validated device, correct cuff, average of two readings) | Every visit | Completed today | 160/100 |
| Examination | 24-hour ambulatory blood pressure monitoring | At diagnosis | Completed today | 24-hour mean 149/94, daytime 154/98, night 140/88; non-dipping |
| Self-management | Home blood pressure readings | Two readings morning and evening for seven days to confirm and after each change; then twice a week, travel days included | Completed today | Seven-day average 152/96 |
| Examination | Weight and BMI | Every visit | Completed today | 78.6 kg, BMI 29.6 |
| Laboratory | Potassium, bicarbonate, creatinine and eGFR (CKD-EPI 1912, race-free) | Two to four weeks after starting or increasing losartan or empagliflozin; then every six months | Completed today | Creatinine 1.21 mg/dL, eGFR 55 (CKD-EPI 1912, race-free); potassium 4.4 mmol/L two weeks ago; panel booked in two weeks after starting losartan and empagliflozin |
| Laboratory | Urine albumin-to-creatinine ratio | Repeat to confirm; about three months after a treatment change; then every six months for G3a A2 | Completed today | 294 mg/g, confirming 286 at intake |
| Laboratory | Calcium, phosphate and parathyroid hormone | At diagnosis of G3a, then every 6 to 12 months | Completed today | Calcium 9.4, phosphate 3.6 mg/dL; parathyroid hormone 58 pg/mL |
| Laboratory | 25-hydroxyvitamin D | At baseline | Completed today | 31 ng/mL |
| Laboratory | Urinalysis with microscopy | At diagnosis | Up to date | At intake: 1+ protein, no blood, bland sediment |
| Imaging | Kidney ultrasound | Once, at the diagnosis of CKD | Completed today | Normal-sized kidneys, mildly increased echogenicity, no obstruction |
| Laboratory | Hemoglobin | Yearly in CKD G3 | Up to date | 12.4 g/dL at intake |
| Survey | Kidney failure risk equation (4-variable), 2- and 5-year | Yearly for G3 to G5 | Completed today | 5-year risk 1.6%, 2-year risk under 1% |
| Survey | 10-year ASCVD risk (Pooled Cohort Equations) | Yearly | Completed today | 7.9%, intermediate; CKD a risk enhancer |
| Laboratory | Lipid panel and ALT | 4 to 12 weeks after starting a statin, then yearly | Up to date | LDL 174 mg/dL at intake; atorvastatin started today |
| Examination | Baseline ECG, TSH and A1c | At the diagnosis of hypertension | Up to date | Done at intake: LVH by voltage; TSH 1.9; A1c 5.4% |
| Imaging | Echocardiogram | At diagnosis of stage 2 hypertension or LVH on ECG | Ordered | Booked for the next visit |
| Examination | Fundus examination | Yearly | Up to date | At intake: mild arteriolar narrowing, no hemorrhages |
| Medication safety | Medicine safety and reconciliation: no NSAIDs, sick-day rules, dizziness, ankle swelling, genital infection, cough, adherence across time zones | Every visit | Completed today | No NSAIDs; sick-day card given; losartan, empagliflozin and atorvastatin explained, including genital hygiene on empagliflozin |
| Self-management | Sodium and diet counseling | Every visit | Completed today | Video session with the dietitian booked before her next trip |
| Referral | Nephrology review | At diagnosis; then about six months, by video if she prefers | Completed today | Seen by Dr. Achterberg today |
Goal progress:
Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race (2021); A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease (2021); 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (2018); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026)
Follow-up: Potassium and creatinine in two weeks with the echocardiogram. Home readings twice a day for a week after starting, then twice a week. Call for dizziness, fainting, vomiting or diarrhea (hold losartan and empagliflozin), or swelling of the lips or tongue. Next scheduled visit 1917-03-09: two-week check of potassium and creatinine after starting losartan and empagliflozin, home readings, and the echocardiogram. [S]